Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin

Conclusions: EDB-FN is a promising molecular marker for assessing drug resistance. MRMI of EDB-FN with MT218 at a significantly reduced dose can facilitate effective non-invasive assessment and treatment response monitoring of drug-resistant CRC, highlighting its translational potential for active surveillance and management of CRC and other malignancies.

Source: Theranostics - October 3, 2020 Category: Molecular Biology Authors: Amita Vaidya, Nadia Ayat, Megan Buford, Helen Wang, Aman Shankardass, Yiqing Zhao, Hannah Gilmore, Zhenghe Wang, Zheng-Rong Lu Tags: Research Paper Source Type: research